Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEPIDH1M

Next Previous
X
Search
Drug Profile

PEPIDH1M

Alternative Names: Cancer vaccine - Annias Immunotherapeutics; Cytomegalovirus vaccine - Annias Immunotherapeutics; Cytomegalovirus-specific peptide vaccine - Annias Immunotherapeutics; Dendritic cell vaccine - Annias Immunotherapeutics; PEP CMV

Latest Information Update: 04 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University
  • Developer Annias Immunotherapeutics; Duke University
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Glioma; Medulloblastoma

Most Recent Events

  • 31 May 2024 The efficacy and adverse event data from a phase I trial in Glioma and Medulloblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 15 Nov 2023 The University of New South Wales plans a phase I trial in Glioblastoma (Newly diagnosed, Combination therapy) in November 2023 (NCT06132438)
  • 08 Nov 2022 Servier plans a phase I ViCToRy trial for Glioma (Combination therapy, Recurrent) in USA (Intradermal) (NCT05609994)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top